Evidence map›Paper›PMID 36500272›Full record

ArticleMolecules (Basel, Switzerland)2022

Rapid Purification and Formulation of Radiopharmaceuticals via Thin-Layer Chromatography.

Travis S Laferriere-Holloway, Alejandra Rios, Giuseppe Carlucci, R Michael van Dam

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Travis S Laferriere-HollowayDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-4533-4851
Alejandra RiosCrump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095, USA.
Giuseppe CarlucciDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
R Michael van DamDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-2316-0173

Funding

Research Training in Biomedical PhysicsT32EB002101 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Michael F McNitt-Gray · 2003 to 2026
$5.3M
Accelerating the discovery and development of neurotracers via high-throughput radiochemistryR01EB032264 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHATZIIOANNOU, ARION XENOFON, VAN DAM, ROBERT MICHAEL · 2022 to 2025
$2.7M
Optimization and validation of integrated microscale technologies for low-cost, automated production of PET molecular imaging tracers for cancer researchR33CA240201 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2019 to 2021
$1.1M
Novel microscale purification methods for complete microfluidic production of high molar activity PET radiotracersR21EB024243 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2019 to 2020
$429k
NCI NIH HHS R33 CA240201NIBIB NIH HHS R01 EB032264NIBIB NIH HHS R21 EB024243NIBIB NIH HHS T32 EB002101
6 · The paper itself

Abstract

Before formulating radiopharmaceuticals for injection, it is necessary to remove various impurities via purification. Conventional synthesis methods involve relatively large quantities of reagents, requiring high-resolution and high-capacity chromatographic methods (e.g., semi-preparative radio-HPLC) to ensure adequate purity of the radiopharmaceutical. Due to the use of organic solvents during purification, additional processing is needed to reformulate the radiopharmaceutical into an injectable buffer. Recent developments in microscale radiosynthesis have made it possible to synthesize radiopharmaceuticals with vastly reduced reagent masses, minimizing impurities. This enables purification with lower-capacity methods, such as analytical HPLC, with a reduction of purification time and volume (that shortens downstream re-formulation). Still, the need for a bulky and expensive HPLC system undermines many of the advantages of microfluidics. This study demonstrates the feasibility of using radio-TLC for the purification of radiopharmaceuticals. This technique combines high-performance (high-resolution, high-speed separation) with the advantages of a compact and low-cost setup. A further advantage is that no downstream re-formulation step is needed. Production and purification of clinical scale batches of [

Indexed as

MicrofluidicsRadiopharmaceuticalsChromatography, High Pressure LiquidChromatography, Thin LayerRadiochemistryRadiopharmaceuticalsmicroscale radiosynthesisminiaturizationpreparative TLCradiopharmaceuticalsthin-layer chromatography

Identifiers

PMID36500272
PMCPMC9738419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.